Drugs / ROC-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07175038 | Oct 2025 → Mar 2027 expected | pulmonary arterial hypertension, pulmonary hypertension owing to lung disease and/or hypoxia | AllRock Bio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-29 | AllRock Bio, Inc. | Results AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress allrockbio.com ↗
The first-in-human study met its primary endpoint, demonstrating that ROC-101 is safe, well-tolerated, does not cause hypotension, and achieves target engagement—supporting its continued evaluation in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-09 | AllRock Bio, Inc. | AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension allrockbio.com ↗ |
| 2025-09-29 | AllRock Bio, Inc. | AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress allrockbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07175038 ↗ |
| Action | Inhibit | “Oral, daily administered Rho kinase inhibitor” NCT07175038 ↗ |
| Route | Oral | “Oral, daily administered Rho kinase inhibitor” NCT07175038 ↗ |